These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24510488)

  • 41. Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6).
    Bazin R; Lemieux R
    J Immunol Methods; 1989 Jan; 116(2):245-9. PubMed ID: 2783446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simultaneous cloning and selection of hybridomas and transfected cell lines in semisolid media.
    Wognum B; Lee T
    Methods Mol Biol; 2013; 946():133-49. PubMed ID: 23179830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High efficiency creation of human monoclonal antibody-producing hybridomas.
    Dessain SK; Adekar SP; Stevens JB; Carpenter KA; Skorski ML; Barnoski BL; Goldsby RA; Weinberg RA
    J Immunol Methods; 2004 Aug; 291(1-2):109-22. PubMed ID: 15345310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining the immune mechanism with monoclonal antibodies.
    Klinman NR; Denis KA; Sherman LA
    In Vitro; 1981 Dec; 17(12):1029-35. PubMed ID: 6172363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and characterization of monoclonal antibodies against human CD20 in Balb/c mice.
    Sepehr KS; Baradaran B; Majidi J; Abdolalizadeh J; Aghebati L; Shahneh FZ
    Hum Antibodies; 2012; 21(3-4):57-64. PubMed ID: 23549022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two chicken B cell lines resistant to ouabain for the production of chicken monoclonal antibodies.
    Nishinaka S; Akiba H; Nakamura M; Suzuki K; Suzuki T; Tsubokura K; Horiuchi H; Furusawa S; Matsuda H
    J Vet Med Sci; 1996 Nov; 58(11):1053-6. PubMed ID: 8959651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of human monoclonal antibodies by fusion of EBV-activated B cells to a human-mouse hybridoma.
    Foung SK; Engleman EG; Grumet FC
    Methods Enzymol; 1986; 121():168-74. PubMed ID: 3014266
    [No Abstract]   [Full Text] [Related]  

  • 48. Production of stable heterohybridomas producing human monoclonal antibodies.
    Cooper MD; Kirkpatrick R
    Methods Mol Biol; 1995; 45():29-39. PubMed ID: 7550689
    [No Abstract]   [Full Text] [Related]  

  • 49. Development and characterization of mouse hybridomas.
    Mechetner E
    Methods Mol Biol; 2007; 378():1-13. PubMed ID: 18605074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: antigen presentation by rat/mouse hybridoma lines secreting monoclonal antibodies against the nicotinic acetylcholine receptor.
    Zhang YP; Tzartos SJ; Wekerle H
    Eur J Immunol; 1988 Feb; 18(2):211-8. PubMed ID: 2450756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fusion of myeloma cells with immune spleen cells.
    Fuller SA; Takahashi M; Hurrell JG
    Curr Protoc Mol Biol; 2001 May; Chapter 11():Unit11.7. PubMed ID: 18265079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single-step technique for selecting and cloning hybridomas for monoclonal antibody production.
    Davis JM
    Methods Enzymol; 1986; 121():307-22. PubMed ID: 3487692
    [No Abstract]   [Full Text] [Related]  

  • 53. [Establishment of hybridoma secreting anti-mycobacteria monoclonal antibody by using electrofusion technique].
    Guo M; Pan Z; Wang H
    Wei Sheng Wu Xue Bao; 1998 Oct; 38(5):393-5. PubMed ID: 12549406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison and critical analysis of robotized technology for monoclonal antibody high-throughput production.
    Chiarella P; Leuener M; Fasci C; de Marco A; Santini MP; Fazio VM; Sawyer AM
    Biotechnol Prog; 2011; 27(2):571-6. PubMed ID: 21425250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6.
    Harris JF; Hawley RG; Hawley TS; Crawford-Sharpe GC
    J Immunol Methods; 1992 Apr; 148(1-2):199-207. PubMed ID: 1373425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of Neutralizing Antibody.
    Takemasa E; Liu S; Hasegawa H
    Methods Mol Biol; 2018; 1868():79-92. PubMed ID: 30244456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potentiation of hybridoma production by the use of mouse fibroblast conditioned media.
    Walker KZ; Gibson J; Axiak SM; Prentice RL
    J Immunol Methods; 1986 Apr; 88(1):75-81. PubMed ID: 3958499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latent immunization to produce high-affinity monoclonal antibodies to progesterone.
    Siklódi B; Barna-Vetró I; Solti L
    Hybridoma; 1995 Feb; 14(1):79-84. PubMed ID: 7768536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas.
    Glassy MC; Handley HH; Hagiwara H; Royston I
    Proc Natl Acad Sci U S A; 1983 Oct; 80(20):6327-31. PubMed ID: 6604917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Production of human monoclonal antibodies to B lymphocyte cell surface antigens by in vitro immunization and human-human hybridoma technology.
    Power DA; Gerkis V; d'Apice AJ
    Hum Antibodies Hybridomas; 1990; 1(1):34-41. PubMed ID: 2103351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.